vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and Primerica, Inc. (PRI). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($1.3B vs $872.7M, roughly 1.5× Primerica, Inc.). Primerica, Inc. runs the higher net margin — 21.8% vs 7.3%, a 14.5% gap on every dollar of revenue. On growth, Primerica, Inc. posted the faster year-over-year revenue change (8.4% vs 4.8%). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (99.2% CAGR vs 4.2%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Primerica, Inc. is a multi-level marketing company that provides insurance, investment and financial services to middle-income families in the United States and Canada.
HAE vs PRI — Head-to-Head
Income Statement — Q4 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $872.7M |
| Net Profit | $97.3M | $190.1M |
| Gross Margin | 14.9% | — |
| Operating Margin | 83.4% | — |
| Net Margin | 7.3% | 21.8% |
| Revenue YoY | 4.8% | 8.4% |
| Net Profit YoY | -42.0% | 12.4% |
| EPS (diluted) | — | $5.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | $872.7M | ||
| Q4 25 | $339.0M | $853.7M | ||
| Q3 25 | $327.3M | $839.9M | ||
| Q2 25 | $321.4M | $793.3M | ||
| Q1 25 | $330.6M | $804.8M | ||
| Q4 24 | $348.5M | $768.8M | ||
| Q3 24 | $345.5M | $774.1M | ||
| Q2 24 | $336.2M | $803.4M |
| Q1 26 | $97.3M | $190.1M | ||
| Q4 25 | $44.7M | $197.0M | ||
| Q3 25 | $38.7M | $206.8M | ||
| Q2 25 | $34.0M | $178.3M | ||
| Q1 25 | $58.0M | $169.1M | ||
| Q4 24 | $37.5M | $167.1M | ||
| Q3 24 | $33.8M | $164.4M | ||
| Q2 24 | $38.4M | $1.2M |
| Q1 26 | 14.9% | — | ||
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | 98.0% |
| Q1 26 | 83.4% | — | ||
| Q4 25 | 19.9% | 28.9% | ||
| Q3 25 | 17.9% | 32.3% | ||
| Q2 25 | 16.8% | 29.6% | ||
| Q1 25 | 21.6% | 27.5% | ||
| Q4 24 | 16.9% | 64.7% | ||
| Q3 24 | 15.0% | 32.9% | ||
| Q2 24 | 11.8% | 1.0% |
| Q1 26 | 7.3% | 21.8% | ||
| Q4 25 | 13.2% | 23.1% | ||
| Q3 25 | 11.8% | 24.6% | ||
| Q2 25 | 10.6% | 22.5% | ||
| Q1 25 | 17.5% | 21.0% | ||
| Q4 24 | 10.8% | 21.7% | ||
| Q3 24 | 9.8% | 21.2% | ||
| Q2 24 | 11.4% | 0.1% |
| Q1 26 | — | $5.97 | ||
| Q4 25 | $0.95 | $6.11 | ||
| Q3 25 | $0.81 | $6.35 | ||
| Q2 25 | $0.70 | $5.40 | ||
| Q1 25 | $1.17 | $5.05 | ||
| Q4 24 | $0.74 | $4.92 | ||
| Q3 24 | $0.66 | $4.83 | ||
| Q2 24 | $0.74 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $245.4M | $645.8M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $796.3M | $2.5B |
| Total Assets | $2.4B | $14.7B |
| Debt / EquityLower = less leverage | 1.53× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $245.4M | $645.8M | ||
| Q4 25 | $363.4M | $756.2M | ||
| Q3 25 | $296.4M | $644.9M | ||
| Q2 25 | $292.9M | $621.2M | ||
| Q1 25 | $306.8M | $625.1M | ||
| Q4 24 | $320.8M | $687.8M | ||
| Q3 24 | $299.3M | $550.1M | ||
| Q2 24 | $344.4M | $627.3M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $796.3M | $2.5B | ||
| Q4 25 | $911.5M | $2.4B | ||
| Q3 25 | $849.2M | $2.3B | ||
| Q2 25 | $882.3M | $2.3B | ||
| Q1 25 | $820.8M | $2.3B | ||
| Q4 24 | $906.9M | $2.3B | ||
| Q3 24 | $878.9M | $1.9B | ||
| Q2 24 | $905.4M | $2.1B |
| Q1 26 | $2.4B | $14.7B | ||
| Q4 25 | $2.5B | $15.0B | ||
| Q3 25 | $2.4B | $14.8B | ||
| Q2 25 | $2.5B | $14.8B | ||
| Q1 25 | $2.5B | $14.6B | ||
| Q4 24 | $2.5B | $14.6B | ||
| Q3 24 | $2.5B | $14.8B | ||
| Q2 24 | $2.5B | $14.6B |
| Q1 26 | 1.53× | — | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $293.2M | — |
| Free Cash FlowOCF − Capex | $209.9M | — |
| FCF MarginFCF / Revenue | 15.7% | — |
| Capex IntensityCapex / Revenue | 2.5% | — |
| Cash ConversionOCF / Net Profit | 3.01× | — |
| TTM Free Cash FlowTrailing 4 quarters | $417.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $293.2M | — | ||
| Q4 25 | $93.6M | $338.2M | ||
| Q3 25 | $111.3M | $202.9M | ||
| Q2 25 | $17.4M | $162.6M | ||
| Q1 25 | $116.6M | $197.5M | ||
| Q4 24 | $43.8M | $270.6M | ||
| Q3 24 | $48.8M | $207.3M | ||
| Q2 24 | $-27.4M | $173.3M |
| Q1 26 | $209.9M | — | ||
| Q4 25 | $87.2M | — | ||
| Q3 25 | $106.3M | — | ||
| Q2 25 | $13.6M | — | ||
| Q1 25 | $100.9M | — | ||
| Q4 24 | $35.2M | — | ||
| Q3 24 | $39.4M | — | ||
| Q2 24 | $-33.1M | — |
| Q1 26 | 15.7% | — | ||
| Q4 25 | 25.7% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 30.5% | — | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | 11.4% | — | ||
| Q2 24 | -9.8% | — |
| Q1 26 | 2.5% | — | ||
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 1.7% | — |
| Q1 26 | 3.01× | — | ||
| Q4 25 | 2.09× | 1.72× | ||
| Q3 25 | 2.88× | 0.98× | ||
| Q2 25 | 0.51× | 0.91× | ||
| Q1 25 | 2.01× | 1.17× | ||
| Q4 24 | 1.17× | 1.62× | ||
| Q3 24 | 1.44× | 1.26× | ||
| Q2 24 | -0.71× | 147.98× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
